You might love him or you might hate him (I'm obviously one of his fans), but either way Senator Charles Grassley and his passionate staff have shaken up the world of medicine and have made "conflict of interest" a household term.
Recently, I read this article published on the website LawyersandSettlements.com that provides a succinct rundown of Team Grassley's accomplishments. Lawyers, of course, are particularly big Grassley fans because each one of his investigations creates instant jobs for dozens of attorneys on various sides of the issue. Thus, you can count on them to be particularly vigilant and accurate monitors of the COI body count as it rises. For the confused, the overwhelmed, or the plain curious, this article makes for a nice fact sheet.
skip to main |
skip to sidebar
"This is one of the most concise and practical guides that I have ever seen." - Christina M. Delos Reyes, MD
Click the book cover for more information
Keeping Psychiatry Honest Since 2007
New Book! Addiction Treatment—A Carlat Guide
"This is one of the most concise and practical guides that I have ever seen." - Christina M. Delos Reyes, MD
Earn CME Credits Online with The Carlat Psychiatry Report
Subscribe to our RSS Feed!Buy the Carlat Medication Fact Book
Click the book cover for more information
About Dr. Carlat
I am a psychiatrist in Newburyport, Massachusetts and an Associate Clinical Professor of Psychiatry at Tufts Medical School (but note that the opinions expressed in this blog are not those of Tufts). I graduated from the psychiatric residency at Massachusetts General Hospital in 1995, and am the founder and publisher of three CME newsletters: The Carlat Psychiatry Report, The Carlat Child Psychiatry Report, and The Carlat Addiction Treatment Report.
Psychiatry Links
Pharma-Skeptical Sites
Pharma-Friendly Sites
CME Sites
Blog Archive
-
▼
2009
(92)
-
▼
June
(11)
- Psychiatry’s DSM-V Process: Now A Bar Room Brawl
- Team Grassley, a Lawyer's Eye View
- The APA, Power, and the Exclusion of Dissent
- Geodon Ineffective for Bipolar Depression; or, Wat...
- The AMA, Going Reagan, Turns to Bean-Counting Again
- Margaret Soltan on Zachary Stowe
- The Latest Conflict of Interest Poster Child: Dr. ...
- When Greed Happens to Good People: Atul Gawande's ...
- Spurred by Nemeroff Debacle, Emory Reforms Ethics
- Behold the Pri-Med Empire
- Harvard Med School, Jack Connors, and the Manipula...
-
▼
June
(11)
Labels
- 12-step programs (1)
- AA (1)
- AARP (1)
- Abilify (6)
- ACCME (16)
- ACCME report (1)
- ACRE (3)
- Addyi (1)
- ADHD (5)
- Advertising (2)
- Akathisia (2)
- Alan Schatzberg (6)
- Alcoholics Anonymous (1)
- Alison Bass (1)
- Alkermes Pharmaceuticals (1)
- Allen Frances (2)
- Alliance for CME (2)
- Alzheimer's disease (1)
- AMA (4)
- Amen Clinics (2)
- American Academy of Allergy (1)
- American Academy of Orthopaedic Surgeons (1)
- American Board of Medical Specialties (1)
- American College of Cardiology (1)
- American Journal of Psychiatry (2)
- American Medical Association (3)
- American Psychiatric Association (8)
- American Psychiatric News (2)
- American Society of Hypertension (1)
- Anatomy of an Epidemic (1)
- Andrew Wilner (1)
- AndroGel (1)
- Angell (1)
- Antidepressants (3)
- Antidote (1)
- antipsychotics (4)
- Anxiety disorders (1)
- APA (4)
- APA election (2)
- Aplenzin (1)
- Appelbaum (1)
- aripiprazole (1)
- Assurex (1)
- Asthma and Immunology (1)
- Astra Zeneca (11)
- Atlantic Magazine (1)
- BBC (1)
- Behrman (1)
- Bernard Carroll (1)
- bifeprunox (2)
- Billy Rubin's Blog (1)
- binge eating disorder (1)
- BIO 2008 (1)
- Bioethics (1)
- Biomarkers (2)
- bipolar depression (1)
- bipolar disorder (1)
- Blogging (1)
- BlueSpark (1)
- BMJ (1)
- book review (1)
- Boston Globe (3)
- Boston University (1)
- Brain Devices (1)
- Brand(x) (1)
- Bremmer (1)
- Brigham and Woman's Hospital (1)
- Brintellix (1)
- Bristol-Myers Squibb (8)
- British Medical Journal (3)
- bupropion (1)
- BusinessWeek (3)
- CAFE study (1)
- Califf (1)
- California Academy of Family Physicians (1)
- Canadian Medical Association (1)
- Carl Elliott (1)
- Carlat CME Institute (1)
- CATIE trial (1)
- CATR (1)
- CE Measure (1)
- CECentral (1)
- CEJA (5)
- Center for Medicine in the Public Interest (1)
- Cephalon (1)
- Cervero (2)
- Chantix (1)
- Charles Ornstein (1)
- Chicago Tribune (1)
- child psychiatry (1)
- Clawsen (1)
- CME (5)
- CME LLC (1)
- CME Outfitters (1)
- CME Peer Review (2)
- CME Reform (1)
- CME Rogue's Gallery (1)
- CME Zone (2)
- CNS News (1)
- CNS Spectrums (4)
- Coalition for Healthcare Communication (1)
- Colbert (1)
- commercial bias (24)
- Commercial Bias Inventory (1)
- Commercial Support Free CME (1)
- Comparative effectiveness research (1)
- Conflicts of Interest (7)
- Connors (1)
- continuing medical education (1)
- Contrave (1)
- Corruption (2)
- Council of Medical Specialty Societies (1)
- Counter-detailing (2)
- CS2day (1)
- Current Psychiatry (6)
- CVS Caremark (2)
- Cymbalta (3)
- Dallas Leipzig International Valve 2010 (1)
- data-mining (2)
- Dave Davies (1)
- David Kupfer (1)
- David Polly (1)
- Delaware Media Group (1)
- depression (2)
- Depression Central (1)
- DesignWrite (5)
- Deval Patrick (1)
- DeVane (1)
- Devices (1)
- Direct to consumer ads (1)
- dirty thirty (1)
- disclosure (1)
- Dollars for Docs (1)
- Donna Beales (1)
- Donna Norris (1)
- Doug Bremner (1)
- Dowden Health Media (2)
- Dr. Drug Rep (1)
- Dr. RW (1)
- drug companies (1)
- drug reps (3)
- Drug-drug interactions (1)
- DSM-V (6)
- DuBuske (1)
- EEG (1)
- Effexor (4)
- Eli Lilly (16)
- Emory University (6)
- EMSAM (1)
- Epocrates (1)
- Ethics Policies (1)
- Fauber (1)
- FDA (7)
- fibromyalgia (1)
- Flibanserin (1)
- Forest Laboratories (2)
- Free samples (1)
- free speech (1)
- Fresh air (1)
- Frontline (1)
- Fugh-Berman (5)
- Functional neuroimaging (1)
- Furious Seasons (1)
- Gardiner Harris (2)
- Gawande (1)
- generics (1)
- GeneSight (2)
- Genetic Testing (1)
- genetics (1)
- ghostwriting (5)
- gift ban (3)
- GlaxoSmithKline (4)
- Goldberg (2)
- Goodwin (5)
- Goozner (1)
- Governor Deval Patrick (1)
- Grassley (8)
- Great Britain (1)
- Greater Boston (1)
- greed (1)
- Harvard Medical School (1)
- Haymarket Medical (1)
- Health Affairs (1)
- Health care reform (1)
- Health Care Renewal (1)
- HealthGrades (1)
- Heart Rhythm Society (1)
- hired gun (4)
- Hormone replacement therapy (1)
- hospitality (1)
- HSDD (1)
- Hypoactive Sexual Desire Disorder (1)
- i3 CME (4)
- IMS (2)
- In Her Wake (1)
- Indianapolis Star (2)
- industry-free CME (4)
- industry-funded CME (11)
- Insel (2)
- Institute for Continuing Healthcare (1)
- Institute of Medicine (1)
- Invega (2)
- iPhone (1)
- IRINE (1)
- Ivan Goldberg (1)
- JAMA (5)
- James Stein (1)
- Janssen (1)
- Jazz Pharmaceuticals (2)
- Jeffrey Flier (1)
- Jerry Avorn (1)
- John Kelsoe (1)
- John Russell (1)
- Johns Hopkins (2)
- Johnson and Johnson (1)
- Joseph Biederman (4)
- Journal of Clinical Psychiatry (4)
- Judith Graham (1)
- key opinion leaders (1)
- Kickbacks (1)
- Kulongoski (2)
- Latuda (1)
- legal consultation (1)
- Letters and Science (1)
- Lexapro (1)
- Liebowitz (1)
- Lighthouse Learning (1)
- Lisa Cosgrove (1)
- Lizbeth Kowalszyk (1)
- LLC (1)
- Lurasidone (2)
- Luvox CR (1)
- Luvox SR (1)
- M/C Communications (1)
- Macy Foundation (2)
- major depressive disorder (1)
- Manhattan Research (1)
- Marcia Angell (1)
- Marketing tactics (1)
- Martha Rosenberg (1)
- Martin Samuels (1)
- Massachusetts General Hospital (4)
- Massachusetts gift ban (11)
- McAllen (1)
- McCain (1)
- McGeeney (1)
- McMahon Publishing Group (2)
- MDDScore (1)
- Med Page Today (1)
- Medbribe (1)
- Medical Marketing and Media (1)
- Medical Meetings Magazine (3)
- Medical Societies (1)
- Medscape (11)
- Medtronic (2)
- Meghna Chakrabarti (1)
- Melody Peterson (1)
- Memorial Sloan-Kettering (2)
- Mental Health American (1)
- Merck (1)
- Michael First (1)
- Milwaukee Journal Sentinel (2)
- Mina Dulcan (1)
- Minh Uong (1)
- Mother Jones (1)
- Mukherjee (1)
- Nancy Rappaport (1)
- Natasha Singer (1)
- National Physician's Alliance (2)
- NEBA (1)
- Nemeroff (15)
- Nesi (1)
- Neuroinvestment (1)
- Neuroscience education insttitute (1)
- neuroscienceCME (1)
- New Hampshire (2)
- New York State Assembly (1)
- New York Times (5)
- New York Times Magazine (3)
- New Yorker (1)
- Niravam (1)
- Nissen (1)
- Notes from RW (1)
- Novartis (1)
- Nuvigil (1)
- Obama (2)
- Off-label promotion (1)
- On Point (1)
- Open Payments (1)
- opiates (1)
- Oransky (1)
- Oregon (3)
- Oregon Academy of Family Physicians (1)
- Orexigen (1)
- Otsuka (2)
- Pain TV (1)
- Parry (1)
- Partners (2)
- Patent Extenders (1)
- Pathophilia (2)
- Patient Priming (1)
- Paul Simon (1)
- Paul Thacker (1)
- Pew (1)
- Pfizer (5)
- pharma marketing blog (1)
- Pharmaceutical marketing (3)
- pharmacogenetics (1)
- Pharmed Out (2)
- PhRMA code (1)
- Physi (1)
- Physician disclosure (1)
- Physician payments (4)
- Physician Payments Sunshine Act (5)
- Pies (1)
- Placebo controlled trial (3)
- Placebo Journal Blog (1)
- podcast (1)
- Poison Pills (1)
- Policy and Medicine (2)
- practice guidelines committee (1)
- premarin (1)
- Prempro (2)
- prescription data-mining (5)
- Prescription project (1)
- prescriptive privileges (1)
- Pri-Med (1)
- Primary Psychiatry (2)
- Primedia Healthcare (1)
- Pristiq (3)
- PRMS (1)
- Product theaters (1)
- Professional Medical Associations (1)
- promotional speakers (3)
- ProPublica (5)
- Psychiatric Times (3)
- Psychiatry websites (2)
- psychologists (3)
- psychosis (1)
- psychotherapy (2)
- Psynomics (1)
- PV Updates (1)
- QuantiaMD (1)
- Radio Boston (1)
- Rajnish Mago (1)
- Reed Elsevier (1)
- Relman (1)
- Remission (1)
- Reporting on Health (1)
- Research (2)
- Reviews of websites (2)
- Ridge Diagnostics (1)
- Robert DeLeo (1)
- Robert Freedman (1)
- Royal College of Physicians (1)
- Rozerem (1)
- sanofi aventis (1)
- SAPHRIS (2)
- Schatzberg (2)
- Schering-Plough (2)
- Schwarz Pharma (1)
- Schwitzer (1)
- seeding trials (1)
- Senate Aging Committee (2)
- Senate Finance Committee (1)
- Senator Herb Kohl (2)
- SentinelSource (1)
- Sepracor (1)
- Seroquel (11)
- Shahram Ahari (1)
- Sharfstein (1)
- Shire (4)
- Silenor (1)
- Simple and Practical Mental Health (1)
- SmithKline Beecham (1)
- Soltan (2)
- Solvay (3)
- Somaxon (1)
- SPECT (1)
- Spencer (1)
- Spielmans (1)
- Sprout Pharmaceuticals (1)
- Standards for Commercial Support (1)
- Stanford University (2)
- Stephen Stahl (3)
- Sternthal (1)
- Steve DiFillippo (2)
- Steven Stahl (1)
- stimulants (1)
- Stossel (1)
- Stowe (2)
- Strattera (1)
- Sunovion (2)
- super PACs (1)
- surveys (2)
- Symbyax (1)
- Takeda (1)
- Tamar Hosansky (1)
- testosterone (1)
- Thacker (1)
- The Carlat Addiction Treatment Report (1)
- The Carlat Medical Report (1)
- The Carlat Psychiatry Report (1)
- The Infinite Mind (4)
- The Psychiatrist's Program (2)
- Thomas Sullivan (1)
- Thought Broadcast (1)
- Tim Kuklo (1)
- TMS (1)
- Tom Ashbrook (1)
- Tom Sullivan (1)
- Transcranial Magnetic Stimulation (1)
- Tufts (1)
- Unbranded Doctor (1)
- University Diaries (1)
- University of Michigan (1)
- University of North Texas Health Science Center (1)
- University of Wisconsin (3)
- Verispan (1)
- Vermont (2)
- Vermont Psychiatric Association (1)
- Viibryd (1)
- vilazodone (1)
- Vioxx (1)
- Viracept (1)
- vortioxetine (1)
- Vox Medica (1)
- Vyvanse (2)
- Wall Street Journal Health Blog (1)
- Washington Post (1)
- Web Chat (1)
- WebMD (1)
- Website reviews (2)
- Whitaker (1)
- Wilens (1)
- William Carpenter (1)
- William Heisel (2)
- Wired magazine (1)
- Wisconsin Medical Society (1)
- Wood (1)
- Wyeth Pharmaceuticals (12)
- Zimmerman (1)
- Zyprexa (2)
5 comments:
Stay the course, Dr. C. You are better than your enemies. Just curious: Did you really think that your colleagues who have been getting drunk on pharma money would just go away? Do you really think that a blog post was your undoing? I don't think so. "They" are after you because you have integrity. I just wish the rest of this field had your courage. Be strong.
I hope that Senator Grassley invites mental health advocacy organizations to testify. If research can be tainted in fact or appearance by money can't advocacy as well?
In a mental health system long beset by limited resources it is essential that their advocacy efforts go primarily towards addressing the needs of consumers.
Disappointingly, Senator Grassley is against a public health insurance implementation in the United States. The senator believes that if this were to occur, it would harm the private insurance industry.
The senator should know that, with reforms and overhauls, sacrifices are common and necessary.
Of course Grassley's against a public insurance implementation.
Does anyone really think his "twittering" grandstanding reflects any deep-seated feelings for the public good and not his private insurance company backing?
Ha! I hate to say I told you so, but....
http://tinyurl.com/m8g9pd
Anybody who still thinks Chuck Grassley is not a giant cheerleader for Big Insurance is seriously deluded.
Sarah Palin is bad enough with her fearmongering about the "death panel" but St. Chuck of the Medical Reformers reinforces her crazypants talk.
Keep your eyes open, folks, and learn to recognize those grandstanders when you see one.
Post a Comment